Erlotinib Terminated Phase 2 Trials for Relapsed / Recurrent Germ Cell Tumors Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01962896A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors